Real world time trends in antithrombotic treatment for newly diagnosed atrial fibrillation in China: reports from the GLORIA-AF Phase III registry : Trends in antithrombotic therapy use in China.

Liu, Xiaoxia; Feng, Guoze; Marler, Sabrina Vogel; Huisman, Menno V; Lip, Gregory Y H; Ma, Changsheng

Liu, Xiaoxia; Feng, Guoze; Marler, Sabrina Vogel; Huisman, Menno V; Lip, Gregory Y H; Ma, Changsheng.

Afiliación

Liu X; Department of Cardiology, Beijing An Zhen Hospital, Capital Medical University, Chaoyang District, Beijing, 100029, China. dr_lxx@126.com.
Feng G; Boehringer Ingelheim, Shanghai, China.
Marler SV; Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Huisman MV; Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands.
Lip GYH; Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.
Ma C; Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

Thromb J ; 21(1): 83, 2023 Aug 01.

Article en En | MEDLINE | ID: mdl-37528405

Palabras clave

Atrial fibrillation; China; Oral anticoagulation; Prevention; Stroke

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Guideline / Risk_factors_studies Idioma: En Revista: Thromb J Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google